eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

Prognostic value of human papilloma virus (HPV) status and programmed cell death ligand 1 (PD-L1) status in oral tongue cancer

Mateusz Szewczyk
1, 2
,
Julia Ostapowicz
2, 3, 4, 5
,
Igor Piotrowski
2, 3
,
Kamila Ostrowska
1, 2, 3
,
Wiktoria Suchorska
2, 3, 4
,
Wojciech Golusiński
1, 2

  1. Department of Head and Neck Surgery, Poznan University of Medical Sciences, Poland
  2. The Greater Poland Cancer Centre, Poznan, Poland
  3. Radiobiology Laboratory, The Greater Poland Cancer Centre, Poznan, Poland
  4. Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland
  5. Doctoral School, Poznan University of Medical Sciences, Poznan, Poland
Contemp Oncol (Pozn) 2024;
DOI: https://doi.org/10.5114/wo.2024.144760
Online publish date: 2024/11/07
Article files
- Prognostic value.pdf  [0.35 MB]
- Supplementary file S1.pdf  [0.05 MB]
Get citation
 
PlumX metrics:
 
1. Jones BM, Villavisanis DF, Lehrer EJ, Dickstein DR, Sindhu KK, Misiukiewicz KJ, et al. High failure rates in young nonsmoker nondrinkers with squamous cell carcinoma of the oral tongue. Laryngoscope 2023; 133: 1110–1121.
2. Tran Q, Maddineni S, Arnaud EH, Divi V, Megwalu UC, Topf MC, et al. Oral cavity cancer in young, non-smoking, and non-drinking patients: a contemporary review. Crit Rev Oncol Hematol 2023; 190: 104112. DOI: 10.1016/j.critrevonc.2023.104112.
3. Rochefort J, Karagiannidis I, Baillou C, Belin L, Guillot-Delost M, Macedo R, et al. Defining biomarkers in oral cancer according to smoking and drinking status. Front Oncol 2023; 12: 1068979. DOI: 10.3389/fonc.2022.1068979.
4. Sun A, Sharma D, Choi S, Ramamurthy P, Thomson P. Oral cancer in Australia: rising incidence and worsening mortality. J Oral Pathol Med 2023; 52: 328–334.
5. De Oliveira LQR, Almangush A, Al-Samadi A, Salo T, Coletta RD. Prognostic markers for oral cancer: an overview of the current status and directions for future research. J Oral Pathol Med 2023; 52: 288–293.
6. Purkayastha K, Dhar R, Pethusamy K, Srivastava T, Shankar A, Rath G, et al. The issues and challenges with cancer biomarkers. J Cancer Res Ther 2023; 19 (Supplement): S20-S35.
7. Ferris RL, Westra W. Oropharyngeal carcinoma with a special focus on HPV-related squamous cell carcinoma. Annu Rev Pathol Mech Dis 2023; 18: 515–535.
8. Shigeishi H. Association between human papillomavirus and oral cancer: a literature review. Int J Clin Oncol 2023; 28: 982–989.
9. Rajanathadurai J, Sindya J, Madar IH, Perumal E. Exosomal immune checkpoint protein (PD-L1): hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer. Oral Oncol 2024; 151: 106748. DOI: 10.1016/j.oraloncology.2024.106748.
10. Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer 2022; 22: 174–189.
11. Pandiella A, Calvo E, Moreno V, Amir E, Templeton A, Ocana A. Considerations for the clinical development of immuno-oncology agents in cancer. Front Immunol 2023; 14: 1229575. DOI: 10.3389/fimmu.2023.1229575.
12. Xu H, Jia Z, Liu F, Li J, Huang Y, Jiang Y, et al. Biomarkers and experimental models for cancer immunology investigation. Med Comm 2023; 4: e437. DOI: 10.1002/mco2.437.
13. Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, et al. High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One 2015; 10: e0142656. DOI: 10.1371/journal.pone.0142656.
14. Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7: e51862. DOI: 10.1371/journal.pone.0051862.
15. Aragón-Niño Í, Cuesta-Urquía C, González-Martín-Moro J, Morán-Soto M, Pozo-Kreilinger J, Pampín-Martinez M, et al. HPV infection in oral cancer, our experience: prevalence, clinical implications, and current vaccination program in Spain. J Clin Exp Dent 2023; e584–e589. DOI: 10.4317/jced.60514.
16. Katirachi SK, Grønlund MP, Jakobsen KK, Grønhøj C, Von Buchwald C. The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses 2023; 15: 451. DOI: 10.3390/v15020451.
17. 17. Christianto S, Li KY, Huang TH, Su Y. The prognostic value of human papilloma virus infection in oral cavity squamous cell carcinoma: a meta-analysis. Laryngoscope 2022; 132: 1760–1770.
18. De Carvalho Melo BA, Gallo Vilar L, Rodriguez de Oliveira N, Oliveira de Lima P, de Barros Pinheiro M, Pereira Domingueti C, et al. Human papillomavirus infection and oral squamous cell carcinoma – a systematic review. Braz J Otorhinolaryngol 2021; 87: 346–352.
19. Minami K, Kogashiwa Y, Ebihara Y, Nakahira M, Sugasawa M, Fujino T, et al. Human papillomavirus and p16 protein expression as prognostic biomarkers in mobile tongue cancer. Acta Otolaryngol 2017; 137: 1121–1126.
20. Subramaniam N, Nambiar A, Dhar S, Thankappan K, Koyakutty M, Balasubramanian D, et al. Low PDL1 expression in tumour infiltrating lymphocytes predicts local recurrence in oral squamous cell carcinoma. Indian J Surg Oncol 2021; 12: 408–414.
21. Akisada N, Nishimoto K, Takao S, Gion Y, Marunaka H, Tachibana T, et al. PD-L1 expression in tongue squamous cell carcinoma. Med Mol Morphol 2021; 54: 52–59.
22. Soopanit T, Laokulrath N, Chayopasakul V, Pongsapich W. Prognostic value and clinicopathological status of PD-L1 expression and CD8 + TILs in oral squamous cell cancer patients with or without traditional risk factors. Head Neck 2023; 45: 1017–1025.
23. Adeoye J, Tan JY, Ip CM, Choi S, Thomson P. “Fact or fiction?”: oral cavity cancer in nonsmoking, nonalcohol drinking patients as a distinct entity – scoping review. Head Neck 2021; 43: 3662–3680.
24. Kujan O, Van Schaijik B, Farah CS. Immune checkpoint inhibitors in oral cavity squamous cell carcinoma and oral potentially malignant disorders: a systematic review. Cancers 2020; 12: 1937. DOI: 10.3390/cancers12071937.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.